Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome

Bibliography

• Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015;313:949-58
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(Suppl 1):S1-35
   PubMed Web of Science ®Google Scholar
• Marugan-Miguelsanz JM, Ontoria M, Velayos B, et al. Natural history of irritable bowel syndrome. Pediatr Int 2013;55:204-7
   PubMed Web of Science ®Google Scholar
• Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol 2014;20:6759-73
   PubMed Web of Science ®Google Scholar
• Koloski NA, Jones M, Young M, Talley NJ. Differentiation of functional constipation and constipation predominant irritable bowel syndrome based on Rome III criteria: a population-based study. Aliment Pharmacol Ther 2015;10.1111/apt.13149
   Web of Science ®Google Scholar
• Mertz HR. Irritable bowel syndrome. N Engl J Med 2003;349:2136-46
   PubMed Web of Science ®Google Scholar
• Cremonini F, Lembo A. IBS with constipation, functional constipation, painful and non-painful constipation: e Pluribus...Plures? Am J Gastroenterol 2014;109:885-6
   PubMed Web of Science ®Google Scholar
• Shekhar C, Monaghan PJ, Morris J, et al. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology 2013;145:749-57
   PubMed Web of Science ®Google Scholar
• Donowitz M, Singh S, Singh P, et al. Alterations in the proteome of the NHERF1 knockout mouse jejunal brush border membrane vesicles. Physiol Genomics 2010;42A:200-10
   Google Scholar
• Tse CM, Brant SR, Walker MS, et al. Cloning and sequencing of a rabbit cDNA encoding an intestinal and kidney-specific Na+/H+ exchanger isoform (NHE-3). J Biol Chem 1992;267:9340-6
   PubMed Web of Science ®Google Scholar
• Schultheis PJ, Clarke LL, Meneton P, et al. Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger. Nat Genet 1998;19:282-5
   PubMed Web of Science ®Google Scholar
• Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21
   PubMed Web of Science ®Google Scholar
• Doshi JA, Cai Q, Buono JL, et al. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Spec Pharm 2014;20:382-90
   PubMed Web of Science ®Google Scholar
• Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advan ces in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol 2014;20:8867-85
   PubMed Web of Science ®Google Scholar
• Harris MS, Daniels OT. Core aspects of clinical development and trials in chronic idiopathic constipation, constipation - causes, diagnosis and treatment. Catto-Smith A, Editor. InTech 2012. Available from: http://www.intechopen.com/books/constipation-causesdiagnosis- and-treatment/core-aspects-of-clinical-development-and-trials-in-chronic-idiopathic constipation
   Google Scholar
• Camilleri M, Lembo AJ, Lavins BJ, et al. Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide Phase III trials in IBS-C. United Eur Gastroenterol J 2015;3:53-62
   Google Scholar
• Raschi E, De PF. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol 2014;10:293-305
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 2011;106:2154-64
   PubMed Web of Science ®Google Scholar
• Bell N, Carreras C, Charmot D, et al. Compounds and Methods for Inhibiting NHE-Mediated Antiport in the treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders. World Intellectual Property Organization WO2014029984; 2014
   Google Scholar
• Charmot D. Non-systemic drugs: a critical review. Curr Pharm Des 2012;18:1434-45
   PubMed Web of Science ®Google Scholar
• Spencer AG, Jacobs JW, Leadbetter MR, et al. RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Proceedings of the Drug Disease Week 2011, Chicago. Gastroenterology; 2011; 140:S-99
   Google Scholar
• Spencer AG, Labonte ED, Rosenbaum DP, et al. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med 2014;6(227):227ra36
   PubMed Web of Science ®Google Scholar
• Eutamene E, Charmot D, Navre M, Bueno L. Visceral Antinociceptive Effects of RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor on Stress-Induced Colorectal Hypersensitivity to Distension in Rats. Proceedings of the DDW meeting 2011, Chicago IL. Gastroenterology; 2015; 140: S-57-8
   Google Scholar
• Rosenbaum DP, Spencer AG, Jacobs J, Charmot D. The safety, tolerability, systemic exposure, and effect on bowel habits of single and multiple doses of the intestinal sodium re-uptake inhibitor RDX5791 in Normal Healthy Volunteers. Proceeding of the ACG meeting 2011,Washington DC. Am J Gastroenterol 2011;106:S504
   Google Scholar
• Rosenbaum DP. Safety, tolerability, pharmacokinetics and pharmacodynamic of AZD1722 in healthy male and female Japanese subjects. ClinicalTrials.gov Identifier: NCT02176252. 2011, 2015
   Google Scholar
• Rosenbaum DP. The efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C). ClinicalTrials.gov Identifier: NCT01923428. 2014
   Google Scholar
• Block GA. Dose finding study to treat high phosphate levels in the blood. ClinicalTrials.gov identifier: NCT02081534. 2015
   Google Scholar
• A study in CKD patients with type 2 diabetes mellitus and albuminuria. ClinicalTrials.gov Identifier:NCT02081534. 2015
   Google Scholar